Onto better TRAILs for cancer treatment

Cell Death and Differentiation

Volumn 23, Issue 5, 2016, Pages 733-747

  De Miguel, D ^a,b   Lemke, J ^c,e   Anel, A ^a,b   Walczak, H ^c   Martinez Lostao, L ^a,b,d,f  

^a UNIVERSITY OF ZARAGOZA   (Spain)

^b INSTITUTO DE INVESTIGACIÓN SANITARIA ARAGÓN IIS ARAGÓN   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Universidad de Zaragoza Consejo Superior de Investigaciones Científicas   (Spain)

^e UNIVERSITY OF ULM   (Germany)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 10; CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; CONATUMUMAB; CYTOKINE RECEPTOR AGONIST; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DULANERMIN; NANOCARRIER; NANOPARTICLE; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SOLUBLE TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR 3; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR AGONIST; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; TNFSF10 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; DISTRIBUTION HALF-LIFE; ELIMINATION HALF-LIFE; HUMAN; LIVER TOXICITY; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN STABILITY; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; AGONISTS; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; NEOPLASMS; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84959514135     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.174     Document Type: Review

References (215)

1. Melero I, Berman DM, Aznar MA, Korman AJ, Gracia JLP, Haanen J. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 2015; 15: 457-472
2. Bracci L, Schiavoni G, Sistigu A, Belardelli F. Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer. Cell Death Differ 2014; 21: 15-25
3. Kaufmann T, Simon HU. Targeting disease by immunomodulation. Cell Death Differ 2015; 22: 185-186
4. Bremer E, de Bruyn M, Wajant H, Helfrich W. Targeted cancer immunotherapy using ligands of the tumor necrosis factor super-family. Curr Drug Targets 2009; 10: 94-103
5. Gasparini C, Vecchi Brumatti L, Monasta L, Zauli G. TRAIL-based therapeutic approaches for the treatment of pediatric malignancies. Curr Med Chem 2013; 20: 2254-2271
6. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. Biol Chem 1996; 271: 12687-12690
7. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang C-P, Nicholl JK et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682
8. Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5: 157-163
9. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113
10. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J. Characterization of two receptors for TRAIL. FEBS Lett 1997; 416: 329-334
11. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES.Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272: 25417-25420
12. Screaton GR, Mongkolsapaya J, Xu XN, Cowper AE, McMichael AJ, Bell JI. TRICK2, a new alternatively spliced receptor that transduces the cytotoxic signal from TRAIL. Curr Biol 1997; 7: 693-696
13. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway. Immunity 1997; 7: 821-830
14. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N et al. TRAILR2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16: 5386-5397
15. Kayagaki N, Yamaguchi N, Nakayama M, Takeda K, Akiba H, Tsutsui H et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol 1999; 163: 1906-1913
16. Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K et al.Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 1999; 162: 2639-2647
17. Martínez-Lorenzo MJ, Alava MA, Gamen S, Kim KJ, Chuntharapai A, Piñeiro A et al. Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur J Immunol 1998; 28: 2714-2725
18. Sträter J, Walczak H, Pukrop T, Von Müller L, Hasel C, Kornmann M et al. TRAIL and its receptors in the colonic epithelium: a putative role in the defense of viral infections. Gastroenterology 2002; 122: 659-666
19. Sträter J, Hinz U, Walczak H, Mechtersheimer G, Koretz K, Herfarth C et al. Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter. Clin Cancer Res 2002; 8: 3734-3740
20. Spierings DC, de Vries EG, Timens W, Groen HJ, Boezen HM, de Jong S. Expression of TRAIL and TRAIL death receptors in stage III non-small cell lung cancer tumors. Clin Cancer Res 2003; 9: 3397-3405
21. Kurbanov BM, Geilen CC, Fecker LF, Orfanos CE, Eberle J. Efficient TRAIL-R1/DR4- mediated apoptosis in melanoma cells by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Invest Dermatol 2005; 125: 1010-1019
22. Voortman J, Resende TP, Abou El Hassan MA, Giaccone G, Kruyt FA. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 2007; 6: 2103-2112
23. Morizot A, Merino D, Lalaoui N, Jacquemin G, Granci V, Iessi E et al. Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. Cell Death Differ 2011; 18: 700-711
24. Micheau O, Shirley S, Dufour F. Death receptors as targets in cancer. Br J Pharmacol 2013; 169: 1723-1744
25. Herbst RS, Eckhardt SG, Kurzrock R, Ebbinghaus S, O'Dwyer PJ, Gordon MS et al. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J Clin Oncol 2010; 28: 2839-2846
26. Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP et al. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. Clin Oncol 2010; 28: 1527-1533
27. Tuthill MH, Montinaro A, Zinngrebe J, Prieske K, Draber P, Prieske S et al. TRAIL-R2- specific antibodies and recombinant TRAIL can synergise to kill cancer cells. Oncogene 2014; 9: 156
28. Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 2007; 13: 3403-3412
29. Koschny R, Ganten TM, Sykora J, Haas TL, Sprick MR, Kolb A et al. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 2007; 45: 649-658
30. Ganten TM, Koschny R, Sykora J, Schulze-Bergkamen H, Buchler P, Haas TL et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res 2006; 12: 2640-2646
31. Lawrence D, Shahrokh Z, Marsters S, Achilles K, Shih D, Mounho B et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat Med 2001; 7: 383-385
32. Lemke J, von Karstedt S, Zinngrebe J, Walczak H. Getting TRAIL back on track for cancer therapy. Cell Death Differ 2014; 21: 1350-1364
33. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999; 4: 563-571
34. Hymowitz SG, O'Connell MP, Ultsch MH, Hurst A, Totpal K, Ashkenazi A et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/ TRAIL. Biochemistry 2000; 39: 633-640
35. Cha SS, Kim MS, Choi YH, Sung BJ, Shin NK, Shin HC et al. 2. 8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 1999; 11: 253-261
36. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273: 14363-14367
37. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276: 111-113
38. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7: 1003-1006
39. Wallach D, Boldin M, Varfolomeev E, Beyaert R, Vandenabeele P, Fiers W. Cell death induction by receptors of the TNF family: towards a molecular understanding. FEBS Letters 1997; 410: 96-106
40. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis. yet retains an incomplete death domain. Immunity 1997; 7: 813-820
41. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang CP, DuBose RF et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186: 1165-1170
42. Merino D, Lalaoui N, Morizot A, Schneider P, Solary E, Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol 2006; 26: 7046-7055
43. Clancy L, Mruk K, Archer K, Woelfel M, Mongkolsapaya J, Screaton G et al. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA 2005; 102: 18099-18104
44. Gomez-Benito M, Martinez-Lorenzo MJ, Anel A, Marzo I, Naval J. Membrane expression of DR4, DR5 and caspase-8 levels, but not Mcl-1, determine sensitivity of human myeloma cells to Apo2L/TRAIL. Exp Cell Res 2007; 313: 2378-2388
45. Kelley RF, Totpal K, Lindstrom SH, Mathieu M, Billeci K, Deforge L et al. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J Biol Chem 2005; 280: 2205-2212
46. Ganten TM, Haas TL, Sykora J, Stahl H, Sprick MR, Fas SC et al. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ 2004; 11 Suppl 1: S86-S96
47. Bodmer JL, Holler N, Reynard S, Vinciguerra P, Schneider P, Juo P et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nat Cell Biol 2000; 2: 241-243
48. Dickens LS, Boyd RS, Jukes-Jones R, Hughes MA, Robinson GL, Fairall L et al. A death effector domain chain DISC model reveals a crucial role for caspase-8 chain assembly in mediating apoptotic cell death. Mol Cell 2012; 47: 291-305
49. Kuang AA, Diehl GE, Zhang J, Winoto A. FADD is required for DR4- and DR5-mediated apoptosis: lack of trail-induced apoptosis in FADD-deficient mouse embryonic fibroblasts, J Biol Chem 2000; 275: 25065-25068
50. Peter ME. The TRAIL DISCussion: it is FADD and caspase-8! Cell Death Differ 2000; 7: 759-760
51. Kischkel FC, Lawrence DA, Chuntharapai A, Schow P, Kim KJ, Ashkenazi A. Apo2L/ TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 2000; 12: 611-620
52. Chen M, Wang J. Initiator caspases in apoptosis signaling pathways. Apoptosis 2002; 7: 313-319
53. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 2004; 5: 897-907
54. Salvesen GS, Dixit VM. Caspase activation: the induced-proximity model. Proc Natl Acad Sci USA 1999; 96: 10964-10967
55. Muhlethaler-Mottet A, Flahaut M, Bourloud KB, Nardou K, Coulon A, Liberman J et al. Individual caspase-10 isoforms play distinct and opposing roles in the initiation of death receptor-mediated tumour cell apoptosis. Cell Death Dis 2011; 2: e125
56. Ozoren N, El-Deiry WS. Defining characteristics of Types I and II apoptotic cells in response to TRAIL. Neoplasia 2002; 4: 551-557
57. Rudner J, Jendrossek V, Lauber K, Daniel PT, Wesselborg S, Belka C. Type I and type II reactions in TRAIL-induced apoptosis - results from dose-response studies. Oncogene 2005; 24: 130-140
58. Grinberg M, Sarig R, Zaltsman Y, Frumkin D, Grammatikakis N, Reuveny E et al. tBID Homooligomerizes in the mitochondrial membrane to induce apoptosis. J Biol Chem 2002; 277: 12237-12245
59. Li H, Zhu H, Xu C-j, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501
60. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-490
61. Wei MC, Lindsten T, Mootha VK, Weiler S, Gross A, Ashiya M et al. tBID, a membranetargeted death ligand, oligomerizes BAK to release cytochrome c. Genes Dev 2000; 14: 2060-2071
62. Holcik M, Korneluk RG. XIAP, the guardian angel. Nat Rev Mol Cell Biol 2001; 2: 550-556
63. Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DC et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009; 460: 1035-1039
64. Modjtahedi N, Giordanetto F, Madeo F, Kroemer G. Apoptosis-inducing factor: vital and lethal. Trends Cell Biol 2006; 16: 264-272
65. Pardo J, Perez-Galan P, Gamen S, Marzo I, Monleon I, Kaspar AA et al. A role of the mitochondrial apoptosis-inducing factor in granulysin-induced apoptosis. J Immunol 2001; 167: 1222-1229
66. Truneh A, Sharma S, Silverman C, Khandekar S, Reddy MP, Deen KC et al. Temperaturesensitive differential affinity of TRAIL for its receptors. DR5 is the highest affinity receptor. J Biol Chem 2000; 275: 23319-23325
67. De Miguel D, Gallego-Lleyda A, Anel A, Martinez-Lostao L. Liposome-bound TRAIL induces superior DR5 clustering and enhanced DISC recruitment in histiocytic lymphoma U937 cells. Leuk Res 2015; 39: 657-666
68. Muhlenbeck F, Schneider P, Bodmer JL, Schwenzer R, Hauser A, Schubert G et al. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J Biol Chem 2000; 275: 32208-32213
69. Wajant H, Moosmayer D, Wuest T, Bartke T, Gerlach E, Schonherr U et al. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001; 20: 4101-4106
70. Trebing J, El-Mesery M, Schafer V, Weisenberger D, Siegmund D, Silence K et al. CD70- restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants. Cell Death Dis 2014; 5: e1035
71. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S, Gaide O, Martinon F et al. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a deathinducing signaling complex. Mol Cell Biol 2003; 23: 1428-1440
72. Wyzgol A, Muller N, Fick A, Munkel S, Grigoleit GU, Pfizenmaier K et al. Trimer stabilization oligomerization, and antibody-mediated cell surface immobilization improve the activity of soluble trimers of CD27L, CD40L, 41BBL, and glucocorticoid-induced TNF receptor ligand. J Immunol 2009; 183: 1851-1861
73. Schneider P, Holler N, Bodmer JL, Hahne M, Frei K, Fontana A et al. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J Exp Med 1998; 187: 1205-1213
74. O' Reilly LA, Tai L, Lee L, Kruse EA, Grabow S, Fairlie WD et al. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009; 461: 659-663
75. Carrington PE, Sandu C, Wei Y, Hill JM, Morisawa G, Huang T et al. The structure of FADD and its mode of interaction with procaspase-8. Mol Cell 2006; 22: 599-610
76. Scott FL, Stec B, Pop C, Dobaczewska MK, Lee JJ, Monosov E et al. The Fas-FADD death domain complex structure unravels signalling by receptor clustering. Nature 2009; 457: 1019-1022
77. Dickens LS, Powley IR, Hughes MA, MacFarlane M. The 'complexities' of life and death: death receptor signalling platforms. Exp Cell Res 2012; 318: 1269-1277
78. Graves JD, Kordich JJ, Huang TH, Piasecki J, Bush TL, Sullivan T et al. Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. Cancer Cell 2014; 26: 177-189
79. MacFarlane M, Inoue S, Kohlhaas SL, Majid A, Harper N, Kennedy DBJ et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005; 12: 773-782
80. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 2005; 65: 11265-11270
81. Szegezdi E, Reis CR, van der Sloot AM, Natoni A, O'Reilly A, Reeve J et al. Targeting AML through DR4 with a novel variant of rhTRAIL. J Cell Mol Med 2011; 15: 2216-2231
82. Lemke J, Noack A, Adam D, Tchikov V, Bertsch U, Rder C et al. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J Mol Med 2010; 88: 729-740
83. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci USA 2006; 103: 8634-8639
84. Kelley SK, Ashkenazi A. Targeting death receptors in cancer with Apo2L/TRAIL. Curr Opin Pharmacol 2004; 4: 333-339
85. Tur V, van der Sloot AM, Reis CR, Szegezdi E, Cool RH, Samali A et al. DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design. J Biol Chem 2008; 283: 20560-20568
86. Gasparian ME, Chernyak BV, Dolgikh DA, Yagolovich AV, Popova EN, Sycheva AM et al. Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5. Apoptosis 2009; 14: 778-787
87. Reis CR, van der Sloot AM, Natoni A, Szegezdi E, Setroikromo R, Meijer M et al. Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants. Cell Death Dis 2010; 1: e83
88. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997; 388: 190-195
89. Tschopp J, Irmler M, Thome M. Inhibition of fas death signals by FLIPs. Curr Opin Immunol 1998; 10: 552-558
90. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 deathinducing signaling complex. J Biol Chem 2001; 276: 20633-20640
91. Weinlich R, Oberst A, Dillon CP, Janke LJ, Milasta S, Lukens JR et al. Protective roles for caspase-8 and cFLIP in adult homeostasis. Cell Rep 2013; 5: 340-348
92. Pop C, Oberst A, Drag M, Van Raam BJ, Riedl SJ, Green DR et al. FLIP(L) induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity. Biochem J 2011; 433: 447-457
93. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011; 43: 449-463
94. Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson DW et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 2002; 277: 45162-45171
95. Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S et al. c-FLIP (L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002; 21: 3704-3714
96. Boatright KM, Deis C, Denault JB, Sutherlin DP, Salvesen GS. Activation of caspases-8 and -10 by FLIP(L). Biochem J 2004; 382(Pt 2): 651-657
97. Oberst A, Dillon CP, Weinlich R, McCormick LL, Fitzgerald P, Pop C et al. Catalytic activity of the caspase-8-FLIP(L) complex inhibits RIPK3-dependent necrosis. Nature 2011; 471: 363-367
98. van Raam BJ, Salvesen GS. Proliferative versus apoptotic functions of caspase-8 Hetero or homo: the caspase-8 dimer controls cell fate. Biochim Biophys Acta 2012; 1824: 113-122
99. Burns TF, El-Deiry WS. Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach. J Biol Chem 2001; 276: 37879-37886
100. Riley JS, Hutchinson R, McArt DG, Crawford N, Holohan C, Paul I et al. Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer. Cell Death Dis 2013; 5: 481
101. Guseva NV, Rokhlin OW, Taghiyev AF, Cohen MB. Unique resistance of breast carcinoma cell line T47D to TRAIL but not anti-Fas is linked to p43cFLIP(L). Breast Cancer Res Treat 2008; 107: 349-357
102. Geserick P, Drewniok C, Hupe M, Haas TL, Diessenbacher P, Sprick MR et al. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene 2008; 27: 3211-3220
103. Balsas P, López-Royuela N, Galán-Malo P, Anel A, Marzo I, Naval J. Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem Pharmacol 2009; 77: 804-812
104. Palacios C, Yerbes R, Lopez-Rivas A. Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res 2006; 66: 8858-8869
105. Lemke J, von Karstedt S, Abd El Hay M, Conti A, Arce F, Montinaro A et al. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1. Cell Death Differ 2014; 21: 491-502
106. Bratton S, Lewis J, Butterworth M, Duckett C, Cohen G. XIAP inhibition of caspase-3 preserves its association with the Apaf-1 apoptosome and prevents CD95-and Bax-induced apoptosis. Cell Death Differ 2002; 9: 881-892
107. Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K et al. Deathreceptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/ TRAIL. Nat Med 2007; 13: 1070-1077
108. Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR et al. Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 2009; 137: 721-735
109. Austin CD, Lawrence DA, Peden AA, Varfolomeev EE, Totpal K, De Maziere AM et al. Death-receptor activation halts clathrin-dependent endocytosis. Proc Natl Acad Sci USA 2006; 103: 10283-10288
110. Lin Y, Devin A, Cook A, Keane MM, Kelliher M, Lipkowitz S et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase. Mol Cell Biol 2000; 20: 6638-6645
111. Morel J, Audo R, Hahne M, Combe B. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt. J Biol Chem 2005; 280: 15709-15718
112. Tran SE, Holmstrom TH, Ahonen M, Kahari VM, Eriksson JE. MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors. J Biol Chem 2001; 276: 16484-16490
113. Grunert M, Gottschalk K, Kapahnke J, Gundisch S, Kieser A, Jeremias I. The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-kappaB by TRAIL. Cell Death Dis 2012; 3: e414
114. Varfolomeev E, Maecker H, Sharp D, Lawrence D, Renz M, Vucic D et al. Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand. J Biol Chem 2005; 280: 40599-40608
115. Azijli K, Yuvaraj S, van Roosmalen I, Flach K, Giovannetti E, Peters GJ et al. MAPK p38 and JNK have opposing activities on TRAIL-induced apoptosis activation in NSCLC H460 cells that involves RIP1 and caspase-8 and is mediated by Mcl-1. Apoptosis 2013; 18: 851-860
116. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, Zorenkov D et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006; 25: 7434-7439
117. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007; 39: 1462-1475
118. Hoogwater FJ, Nijkamp MW, Smakman N, Steller EJ, Emmink BL, Westendorp BF et al. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010; 138: 2357-2367
119. von Karstedt S, Conti A, Nobis M, Montinaro A, Hartwig T, Lemke J et al. Cancer cellautonomous TRAIL-R signaling promotes KRAS-driven cancer progression, invasion, and metastasis. Cancer Cell 2015; 27: 561-573
120. Holland PM. Death receptor agonist therapies for cancer, which is the right TRAIL? Cytokine Growth Factor Rev 2014; 25: 185-193
121. Dimberg LY, Anderson CK, Camidge R, Behbakht K, Thorburn A, Ford HL. On the TRAIL to successful cancer therapy? Predicting and counteracting resistance against TRAIL-based therapeutics. Oncogene 2013; 32: 1341-1350
122. Thorburn A, Behbakht K, Ford H. TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. Drug Resist Updat 2008; 11: 17-24
123. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005; 12: 228-237
124. Lovric MM, Hawkins CJ. TRAIL treatment provokes mutations in surviving cells. Oncogene 2010; 29: 5048-5060
125. Joy AM, Beaudry CE, Tran NL, Ponce FA, Holz DR, Demuth T et al. Migrating glioma cells activate the PI3-K pathway and display decreased susceptibility to apoptosis. J Cell Sci 2003; 116(Pt 21): 4409-4417
126. Sanlioglu AD, Dirice E, Aydin C, Erin N, Koksoy S, Sanlioglu S. Surface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 2005; 5: 54
127. Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, Savas B et al. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma. Int J Radiat Oncol Biol Phys 2007; 69: 716-723
128. Kelley SK, Harris LA, Xie D, Deforge L, Totpal K, Bussiere J et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J Pharmacol Exp Ther 2001; 299: 31-38
129. Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escandon E. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab Dispos 2004; 32: 1230-1238
130. Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S et al. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ 2008; 15: 751-761
131. Dhein J, Daniel PT, Trauth BC, Oehm A, Moller P, Krammer PH. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 1992; 149: 3166-3173
132. Youn YS, Shin MJ, Chae SY, Jin CH, Kim TH, Lee KC. Biological and physicochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Biotechnol Lett 2007; 29: 713-721
133. Ashkenazi A, Pai RC, Fong S, Leung S, Lawrence DA, Marsters SA et al. Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162
134. Ichikawa K, Liu W, Zhao L, Wang Z, Liu D, Ohtsuka T et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity. Nat Med 2001; 7: 954-960
135. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 2000; 6: 564-567
136. Hao C, Song JH, Hsi B, Lewis J, Song DK, Petruk KC et al. TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice. Cancer Res 2004; 64: 8502-8506
137. Kasubhai SM, Bendell JC, Kozloff M, Kapp AV, Ashkenazi A, Royer-Joo S et al. Phase Ib study of dulanermin combined with FOLFIRI (with or without bevacizumab [BV]) in previously treated patients (Pts) with metastatic colorectal cancer (mCRC). J Clin Oncol 2012; 30 (suppl; abstr 3543)
138. Soria JC, Mark Z, Zatloukal P, Szima B, Albert I, Juhasz E et al. Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 4442-4451
139. Wainberg ZA, Messersmith WA, Peddi PF, Kapp AV, Ashkenazi A, Royer-Joo S et al. A phase 1B study of dulanermin in combination with modified FOLFOX6 plus bevacizumab in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2013; 12: 248-254
140. Yee L, Burris HA, Kozloff M, Wainberg Z, Pao M, Skettino S et al. Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): preliminary results. J Clin Oncol 2009; 27: 15s (suppl; abstr 4129)
141. Yee L, Fanale M, Dimick K, Calvert S, Robins C, Ing J et al. A phase IB safety and pharmacokinetic (PK) study of recombinant human Apo2L/TRAIL in combination with rituximab in patients with low-grade non-Hodgkin lymphoma. 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007; 25(June 20 Supplement): 8078
142. Rozanov DV, Savinov AY, Golubkov VS, Rozanova OL, Postnova TI, Sergienko EA et al. Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells. Mol Cancer Ther 2009; 8: 1515-1525
143. Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebald W et al. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ 2007; 14: 2021-2034
144. Schneider B, Munkel S, Krippner-Heidenreich A, Grunwald I, Wels WS, Wajant H et al. Potent antitumoral activity of TRAIL through generation of tumor-targeted single-chain fusion proteins. Cell Death Dis 2010; 1: e68
145. Siegemund M, Pollak N, Seifert O, Wahl K, Hanak K, Vogel A et al. Superior antitumoral activity of dimerized targeted single-chain TRAIL fusion proteins under retention of tumor selectivity. Cell Death Dis 2012; 3: e295
146. Muller N, Schneider B, Pfizenmaier K, Wajant H. Superior serum half life of albumin tagged TNF ligands. Biochem Biophys Res Commun 2010; 396: 793-799
147. Crawford J. Clinical benefits of pegylated proteins in oncology. Cancer Treat Rev 2002; 28: 1-2
148. Crawford J. Clinical uses of pegylated pharmaceuticals in oncology. Cancer Treat Rev 2002; 28: 7-11
149. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2: 214-221
150. Chae SY, Kim TH, Park K, Jin CH, Son S, Lee S et al. Improved antitumor activity and tumor targeting of NH(2)-terminal-specific PEGylated tumor necrosis factor-related apoptosisinducing ligand. Mol Cancer Ther 2010; 9: 1719-1729
151. Jiang HH, Kim TH, Lee S, Chen X, Youn YS, Lee KC. PEGylated TNF-related apoptosisinducing ligand (TRAIL) for effective tumor combination therapy. Biomaterials 2011; 32: 8529-8537
152. Kim TH, Jiang HH, Park CW, Youn YS, Lee S, Chen X et al. PEGylated TNF-related apoptosis-inducing ligand (TRAIL)-loaded sustained release PLGA microspheres for enhanced stability and antitumor activity. J Control Release 2011; 150: 63-69
153. Kim TH, Jiang HH, Youn YS, Park CW, Lim SM, Jin CH et al. Preparation and characterization of Apo2L/TNF-related apoptosis-inducing ligand-loaded human serum albumin nanoparticles with improved stability and tumor distribution. J Pharm Sci 2011; 100: 482-491
154. Lim SM, Kim TH, Jiang HH, Park CW, Lee S, Chen X et al. Improved biological half-life and anti-tumor activity of TNF-related apoptosis-inducing ligand (TRAIL) using PEG-exposed nanoparticles. Biomaterials 2011; 32: 3538-3546
155. Koschny R, Walczak H, Ganten T. The promise of TRAIL-potential and risks of a novel anticancer therapy. J Mol Med 2007; 85: 923-935
156. Kruyt FA. TRAIL and cancer therapy. Cancer Lett 2008; 263: 14-25
157. Mahalingam D, Szegezdi E, Keane M, de Jong S, Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL? Cancer Treat Rev 2009; 35: 280-288
158. Mellier G, Huang S, Shenoy K, Pervaiz S. TRAILing death in cancer. Mol Aspects Med 2010; 31: 93-112
159. Newsom-Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis 2009; 14: 607-623
160. Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7: 771-782
161. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009; 71: 409-419
162. Stylianopoulos T. EPR-effect: utilizing size-dependent nanoparticle delivery to solid tumors. Ther Deliv 2013; 4: 421-423
163. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011; 63: 136-151
164. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug Chem 2010; 21: 797-802
165. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res 1986; 46(12 Pt 1): 6387-6392
166. Torchilin V. Tumor delivery of macromolecular drugs based on the EPR effect. Adv Drug Deliv Rev 2011; 63: 131-135
167. Choi SH, Byeon HJ, Choi JS, Thao L, Kim I, Lee ES et al. Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. J Control Release 2015; 197: 199-207
168. Bae S, Ma K, Kim TH, Lee ES, Oh KT, Park ES et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 2012; 33: 1536-1546
169. Kim H, Jeong D, Kang HE, Lee KC, Na K. A sulfate polysaccharide/TNF-related apoptosisinducing ligand (TRAIL) complex for the long-term delivery of TRAIL in poly(lactic-coglycolic acid) (PLGA) microspheres. J Pharm Pharmacol 2013; 65: 11-21
170. Perlstein B, Finniss SA, Miller C, Okhrimenko H, Kazimirsky G, Cazacu S et al. TRAIL conjugated to nanoparticles exhibits increased anti-tumor activities in glioma cells and glioma stem cells in vitro and in vivo. Neuro Oncol 2013; 15: 29-40
171. Martinez-Lostao L, Garcia-Alvarez F, Basanez G, Alegre-Aguaron E, Desportes P, Larrad L et al. Liposome-bound APO2L/TRAIL is an effective treatment in a rabbit model of rheumatoid arthritis. Arthritis Rheum 2010; 62: 2272-2282
172. De Miguel D, Basanez G, Sanchez D, Malo PG, Marzo I, Larrad L et al. Liposomes decorated with Apo2L/TRAIL overcome chemoresistance of human hematologic tumor cells. Mol Pharm 2013; 10: 893-904
173. Guo L, Fan L, Pang Z, Ren J, Ren Y, Li J et al. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J Control Release 2011; 154: 93-102
174. Guo L, Fan L, Ren J, Pang Z, Ren Y, Li J et al. A novel combination of TRAIL and doxorubicin enhances antitumor effect based on passive tumor-targeting of liposomes. Nanotechnology 2011; 22: 265105
175. Guo L, Fan L, Ren J, Pang Z, Ren Y, Li J et al. Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer. Int J Nanomedicine 2012; 7: 1449-1460
176. Sun X, Pang Z, Ye H, Qiu B, Guo L, Li J et al. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. Biomaterials 2012; 33: 916-924
177. Seifert O, Pollak N, Nusser A, Steiniger F, Ruger R, Pfizenmaier K et al. Immuno- LipoTRAIL: targeted delivery of TRAIL-functionalized liposomal nanoparticles. Bioconjug Chem 2014; 25: 879-887
178. Mitchell MJ, Wayne E, Rana K, Schaffer CB, King MR. TRAIL-coated leukocytes that kill cancer cells in the circulation. Proc Natl Acad Sci USA 2014; 111: 930-935
179. Loi M, Becherini P, Emionite L, Giacomini A, Cossu I, Destefanis E et al. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib. J Control Release 2014; 192: 157-166
180. Fan Y, Zhang Q. Development of liposomal formulations: from concept to clinical investigations. Asian J Pharm Sci 2013; 8: 81-87
181. Arajo Lopes SCd, Santos Giuberti Cd, Ribeiro TG, Santos Ferreira Dd, Amaral Leite E.Cristina M. Liposomes as carriers of anticancer drugs. In: Rangel L (ed). Cancer Treatment - Conventional and Innovative Approaches. InTech. : Viena, Austria, 2013
182. Ke W, Shao K, Huang R, Han L, Liu Y, Li J et al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials 2009; 30: 6976-6985
183. de Bruyn M, Bremer E, Helfrich W. Antibody-based fusion proteins to target death receptors in cancer. Cancer Lett 2013; 332: 175-183
184. Kortt AA, Dolezal O, Power BE, Hudson PJ. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng 2001; 18: 95-108
185. Stieglmaier J, Bremer E, Kellner C, Liebig TM, ten Cate B, Peipp M et al. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol Immunother 2008; 57: 233-246
186. Ten Cate B, Bremer E, de Bruyn M, Bijma T, Samplonius D, Schwemmlein M, et al. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia. 2009, 23 1389-1397.
187. Yan C, Li S, Li Z, Peng H, Yuan X, Jiang L et al. Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: a double-target therapy against non-Hodgkin's lymphoma. Mol Pharm 2013; 10: 142-151
188. de Bruyn M, Rybczynska AA, Wei Y, Schwenkert M, Fey GH, Dierckx RA et al. Melanomaassociated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo. Mol Cancer 2010; 9: 301
189. Bremer E, de Bruyn M, Samplonius DF, Bijma T, ten Cate B, de Leij LF et al. Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFRpositive tumor cells. J Mol Med (Berl) 2008; 86: 909-924
190. Bremer E, van Dam GM, de Bruyn M, van Riezen M, Dijkstra M, Kamps G et al. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Mol Ther 2008; 16: 1919-1926
191. Wahl K, Siegemund M, Lehner F, Vondran F, Nussler A, Langer F et al. Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib. Hepatology 2013; 57: 625-636
192. Aronin A, Amsili S, Prigozhina TB, Tzdaka K, Rachmilewitz J, Shani N et al. Fn14 TRAIL effectively inhibits hepatocellular carcinoma growth. PLoS One 2013; 8: e77050
193. Razmara M, Hilliard B, Ziarani AK, Murali R, Yellayi S, Ghazanfar M et al. Fn14-TRAIL, a chimeric intercellular signal exchanger, attenuates experimental autoimmune encephalomyelitis. Am J Pathol 2009; 174: 460-474
194. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008; 7: 411-425
195. El-Mesery M, Trebing J, Schafer V, Weisenberger D, Siegmund D, Wajant H. CD40- directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells. Cell Death Dis 2013; 4: e916
196. de Bruyn M, Wei Y, Wiersma VR, Samplonius DF, Klip HG, van der Zee AG et al. Cell surface delivery of TRAIL strongly augments the tumoricidal activity of T cells. Clin Cancer Res 2011; 17: 5626-5637
197. Abouzahr-Rifai S, Hasmim M, Boukerche H, Hamelin J, Janji B, Jalil A et al. Resistance of tumor cells to cytolytic T lymphocytes involves Rho-GTPases and focal adhesion kinase activation. J Biol Chem 2008; 283: 31665-31672
198. Chouaib S, Meslin F, Thiery J, Mami-Chouaib F. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer. Clin Immunol 2009; 130: 34-40
199. Hallermalm K, De Geer A, Kiessling R, Levitsky V, Levitskaya J. Autocrine secretion of Fas ligand shields tumor cells from Fas-mediated killing by cytotoxic lymphocytes. Cancer Res 2004; 64: 6775-6782
200. Lee HM, Timme TL, Thompson TC. Resistance to lysis by cytotoxic T cells: a dominant effect in metastatic mouse prostate cancer cells. Cancer Res 2000; 60: 1927-1933
201. Otten HG, van Ginkel WG, Hagenbeek A, Petersen EJ. Prevalence and clinical significance of resistance to perforin- and FAS-mediated cell death in leukemia. Leukemia 2004; 18: 1401-1405
202. Wiersma VR, de Bruyn M, Shi C, Gooden MJ, Wouters MC, Samplonius DF et al. C-type lectin-like molecule-1 (CLL1)-targeted TRAIL augments the tumoricidal activity of granulocytes and potentiates therapeutic antibody-dependent cell-mediated cytotoxicity. MAbs 2015; 7: 321-330
203. Cao L, Du P, Jiang SH, Jin GH, Huang QL, Hua ZC. Enhancement of antitumor properties of TRAIL by targeted delivery to the tumor neovasculature. Mol Cancer Ther 2008; 7: 851-861
204. Max R, Gerritsen RR, Nooijen PT, Goodman SL, Sutter A, Keilholz U et al. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas. Int J Cancer 1997; 71: 320-324
205. Natali PG, Hamby CV, Felding-Habermann B, Liang B, Nicotra MR, Di Filippo F et al. Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res 1997; 57: 1554-1560
206. Kemperman H, Wijnands YM, Roos E. alphaV Integrins on HT-29 colon carcinoma cells: adhesion to fibronectin is mediated solely by small amounts of alphaVbeta6, and alphaVbeta5 is codistributed with actin fibers. Exp Cell Res 1997; 234: 156-164
207. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279: 377-380
208. Carreiras F, Denoux Y, Staedel C, Lehmann M, Sichel F, Gauduchon P. Expression and localization of alpha v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol Oncol 1996; 62: 260-267
209. Gieffers C, Kluge M, Merz C, Sykora J, Thiemann M, Schaal R et al. APG350 induces superior clustering of TRAIL receptors and shows therapeutic antitumor efficacy independent of cross-linking via Fcgamma receptors. Mol Cancer Ther 2013; 12: 2735-2747
210. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D et al. An Fcgamma receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell 2011; 19: 101-113
211. Seifert O, Plappert A, Fellermeier S, Siegemund M, Pfizenmaier K, Kontermann RE. Tetravalent antibody-scTRAIL fusion proteins with improved properties. Mol Cancer Ther 2014; 13: 101-111
212. De Miguel D, Gallego-Lleyda A, Galan-Malo P, Rodriguez-Vigil C, Marzo I, Anel A et al. Immunotherapy with liposome-bound TRAIL overcomes partial protection to soluble TRAIL-induced apoptosis offered by down-regulation of Bim in leukemic cells. Clin Transl Oncol 2015; 17: 657-667
213. Nair PM, Flores H, Gogineni A, Marsters S, Lawrence DA, Kelley RF et al. Enhancing the antitumor efficacy of a cell-surface death ligand by covalent membrane display. Proc Natl Acad Sci USA 2015; 112: 5679-5684
214. Assohou-Luty C, Gerspach J, Siegmund D, Muller N, Huard B, Tiegs G et al. A CD40- CD95L fusion protein interferes with CD40L-induced prosurvival signaling and allows membrane CD40L-restricted activation of CD95. J Mol Med (Berl) 2006; 84: 785-797
215. Zhang HY, Man JH, Liang B, Zhou T, Wang CH, Li T et al. Tumor-targeted delivery of biologically active TRAIL protein. Cancer Gene Ther 2010; 17: 334-343